Tag
The ReCCLAIM II trial demonstrates that rapid systemic hypothermia during mechanical thrombectomy for large-vessel occlusion stroke is feasible without delaying reperfusion, showing trends toward reduced infarct volume but raising safety co
This review elucidates the prognostic significance of HARM and GLOS as imaging biomarkers after mechanical thrombectomy, highlighting their associations with early neurological outcomes and infarct progression.
A randomized clinical trial comparing individualized versus standard blood pressure control during mechanical thrombectomy for ischemic stroke showed no significant difference in 90-day functional outcomes or safety.
The MAD-MT score integrates clinical and procedural factors to optimize mechanical thrombectomy decisions in distal and medium vessel occlusion strokes, guiding tailored treatment and improving functional outcomes.
In a post hoc analysis of the DISTAL trial, mechanical thrombectomy plus best medical treatment preserved more threatened brain tissue than medical treatment alone in medium or distal vessel occlusion stroke, and better tissue preservation
In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.
In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.
This review synthesizes recent evidence comparing ‘mothership’ and ‘drip-and-ship’ strategies in acute ischemic stroke, highlighting functional benefits of direct transport and the critical 43-minute delay threshold.
In a multicenter retrospective study, early mechanical thrombectomy within 12 hours of pulmonary embolism diagnosis improved pulmonary artery pressure reduction and reduced intubation, but did not significantly lower in-hospital mortality.
The BRAVO study provides critical evidence that while IV thrombolysis improves recovery in isolated vertebral artery occlusion, endovascular treatment may increase risks unless reserved for severe cases.
The STORM-PE trial, the first randomized controlled trial of its kind, demonstrates that computer-assisted vacuum thrombectomy (CAVT) significantly improves right ventricular recovery and reduces clot burden compared to anticoagulation alon
Recent multi-site randomized evidence demonstrates that adding intravenous argatroban or eptifibatide to standard thrombolysis within 3 hours of stroke onset does not improve functional recovery and is associated with increased mortality, i
The SUMMIT MAX randomized trial demonstrates that the super large bore HiPoint reperfusion system is noninferior to the Vecta system in reperfusion success and safety for acute ischemic stroke due to large vessel occlusion.
Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.
